Barclays PLC Cuts Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Barclays PLC cut its holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 93.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 30,248 shares of the company's stock after selling 434,704 shares during the period. Barclays PLC owned approximately 0.06% of PMV Pharmaceuticals worth $45,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. ArrowMark Colorado Holdings LLC increased its holdings in PMV Pharmaceuticals by 30.0% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 3,647,291 shares of the company's stock valued at $5,434,000 after buying an additional 842,509 shares during the period. Sio Capital Management LLC increased its stake in PMV Pharmaceuticals by 18.7% in the third quarter. Sio Capital Management LLC now owns 3,214,239 shares of the company's stock valued at $4,789,000 after acquiring an additional 505,831 shares during the last quarter. PFM Health Sciences LP raised its position in PMV Pharmaceuticals by 57.7% during the third quarter. PFM Health Sciences LP now owns 2,011,040 shares of the company's stock valued at $2,996,000 after purchasing an additional 735,578 shares in the last quarter. BML Capital Management LLC lifted its stake in PMV Pharmaceuticals by 29.0% during the third quarter. BML Capital Management LLC now owns 1,688,772 shares of the company's stock worth $2,516,000 after purchasing an additional 379,375 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of PMV Pharmaceuticals by 36.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 353,837 shares of the company's stock valued at $527,000 after purchasing an additional 93,809 shares in the last quarter. 90.20% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer raised PMV Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $6.00 price objective on the stock in a research note on Friday, November 8th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $5.50.

PMV Pharmaceuticals Stock Performance

Shares of PMV Pharmaceuticals stock traded down $0.05 on Friday, hitting $1.46. The stock had a trading volume of 438,988 shares, compared to its average volume of 164,265. The stock has a 50 day moving average of $1.58 and a 200 day moving average of $1.57. PMV Pharmaceuticals, Inc. has a twelve month low of $1.40 and a twelve month high of $2.56. The firm has a market capitalization of $75.55 million, a P/E ratio of -1.46 and a beta of 1.46.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). Equities analysts expect that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.